Everpar Advisors LLC Acquires New Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Everpar Advisors LLC acquired a new position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 1,251 shares of the medical equipment provider’s stock, valued at approximately $422,000.

A number of other hedge funds and other institutional investors have also modified their holdings of ISRG. WCM Investment Management LLC purchased a new stake in shares of Intuitive Surgical during the 4th quarter worth about $575,536,000. International Assets Investment Management LLC lifted its holdings in Intuitive Surgical by 32,360.5% in the fourth quarter. International Assets Investment Management LLC now owns 686,865 shares of the medical equipment provider’s stock worth $231,721,000 after purchasing an additional 684,749 shares during the period. Alphinity Investment Management Pty Ltd boosted its stake in Intuitive Surgical by 113.2% during the fourth quarter. Alphinity Investment Management Pty Ltd now owns 1,276,158 shares of the medical equipment provider’s stock valued at $430,525,000 after buying an additional 677,455 shares in the last quarter. J.P. Morgan Private Wealth Advisors LLC acquired a new position in shares of Intuitive Surgical in the 3rd quarter worth $178,667,000. Finally, Quadrature Capital Ltd raised its stake in Intuitive Surgical by 466.2% during the 3rd quarter. Quadrature Capital Ltd now owns 340,644 shares of the medical equipment provider’s stock valued at $99,601,000 after purchasing an additional 280,480 shares during the period. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Stock Down 2.1 %

Shares of NASDAQ ISRG traded down $8.28 on Wednesday, hitting $380.37. The company had a trading volume of 1,107,969 shares, compared to its average volume of 1,601,620. The firm has a market capitalization of $134.92 billion, a P/E ratio of 68.66, a PEG ratio of 4.93 and a beta of 1.39. The business has a 50 day moving average of $385.34 and a two-hundred day moving average of $351.97. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.10. The business had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The firm’s revenue was up 11.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.00 EPS. On average, sell-side analysts anticipate that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current year.

Insider Activity

In related news, EVP Robert Desantis sold 1,498 shares of Intuitive Surgical stock in a transaction that occurred on Friday, April 26th. The shares were sold at an average price of $369.92, for a total transaction of $554,140.16. Following the transaction, the executive vice president now owns 5,507 shares of the company’s stock, valued at approximately $2,037,149.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Alan J. Levy sold 2,000 shares of the stock in a transaction that occurred on Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total transaction of $741,400.00. Following the transaction, the director now owns 25,319 shares in the company, valued at $9,385,753.30. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Robert Desantis sold 1,498 shares of the business’s stock in a transaction that occurred on Friday, April 26th. The shares were sold at an average price of $369.92, for a total value of $554,140.16. Following the completion of the sale, the executive vice president now owns 5,507 shares of the company’s stock, valued at $2,037,149.44. The disclosure for this sale can be found here. In the last quarter, insiders have sold 147,927 shares of company stock valued at $57,064,459. 0.80% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research firms recently issued reports on ISRG. BTIG Research upped their price objective on shares of Intuitive Surgical from $412.00 to $421.00 and gave the stock a “buy” rating in a report on Friday, April 19th. Stifel Nicolaus boosted their price objective on shares of Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a research report on Monday, April 8th. Barclays lifted their target price on Intuitive Surgical from $385.00 to $430.00 and gave the stock an “overweight” rating in a research note on Thursday, January 25th. Truist Financial lifted their price target on shares of Intuitive Surgical from $390.00 to $435.00 and gave the company a “buy” rating in a research report on Wednesday, January 24th. Finally, Jefferies Financial Group lifted their price target on shares of Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a report on Friday, April 19th. Five research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $396.17.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.